This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2011 Mar 16;2(3):116-7.

doi: 10.1021/cn100113g.

ACS chemical neuroscience molecule spotlight on gilenya (fingolimod; FTY720)

Corey R Hopkins¹

Affiliations

Affiliation

¹ Department of Pharmacology and Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee 37232-6600, United States.

PMID: 22778861
PMCID: PMC3369739
DOI: 10.1021/cn100113g

Review

ACS chemical neuroscience molecule spotlight on gilenya (fingolimod; FTY720)

Corey R Hopkins. ACS Chem Neurosci. 2011.

. 2011 Mar 16;2(3):116-7.

doi: 10.1021/cn100113g.

Author

Corey R Hopkins¹

Affiliation

¹ Department of Pharmacology and Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee 37232-6600, United States.

PMID: 22778861
PMCID: PMC3369739
DOI: 10.1021/cn100113g

No abstract available

PubMed Disclaimer

Similar articles

FTY720 and central memory: out of sight, out of mind.
Slavin AJ, Zamvil SS. Slavin AJ, et al. Neurology. 2010 Aug 3;75(5):388-9. doi: 10.1212/WNL.0b013e3181eee298. Epub 2010 Jul 7. Neurology. 2010. PMID: 20610831 No abstract available.
Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Chiba K, Adachi K. Chiba K, et al. Future Med Chem. 2012 Apr;4(6):771-81. doi: 10.4155/fmc.12.25. Future Med Chem. 2012. PMID: 22530640 Review.
The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulation.
Haghikia A, Gold R. Haghikia A, et al. Am J Pathol. 2010 Jun;176(6):2599-601. doi: 10.2353/ajpath.2010.100200. Epub 2010 Apr 15. Am J Pathol. 2010. PMID: 20395429 Free PMC article.
Trial watch: Phase III promise for oral multiple sclerosis therapy.
[No authors listed] [No authors listed] Nat Rev Drug Discov. 2009 Feb;8(2):98. doi: 10.1038/nrd2821. Nat Rev Drug Discov. 2009. PMID: 19180099 No abstract available.
[FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis].
Klatt J, Hartung HP, Hohlfeld R. Klatt J, et al. Nervenarzt. 2007 Oct;78(10):1200-8. doi: 10.1007/s00115-007-2298-9. Nervenarzt. 2007. PMID: 17668161 Review. German.

See all similar articles

References

1. Compston A.; Coles A. (2002) Multiple sclerosis. Lancet 359, 1221–1231. - PubMed
1. Rosati G. (2001) The prevalence of multiple sclerosis in the world: an update. Neurol. Sci. 22, 117–139. - PubMed
1. Lublin F. D.; Baier M.; Cutter G. (2003) Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 61, 1528–1532. - PubMed
1. Niino M.; Sasaki H. (2010) An update on the treatment options for multiple sclerosis. Expert Rev. Clin. Immunol. 6, 77–88. - PubMed
1. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226755.htm.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information